Entry Detail


General Information

Database ID:TRD00249
Confidence:Median
Contents:>> tsRNA Information
>> tsRNA Association Statistics
>> Disease Information
>> Disease Association Statistics
>> Evidence Support
>> Reference



tsRNA Information

tsRNA Name:tiRNA-Lys-CTT-001
tsRNA Type:5'-tiRNA
Amino acid and Anticodon:LysCTT
Sequence:GCCCGGCTAGCTCAGTCGGTAGAGCATGAGACCC
Related Target:N/A
Predicted Target:NFKBID//EBI3//RPS6KA2//JPH1//WDR54//MOB2//GULP1//SEC61A1//PES1//PLXNA1
External Links:
MINTbase ID:tRF-34-PSQP4PW3FJI0EJ
tRFdb ID:N/A

[1] gtRNAdb_ID:tRNA-Lys-CTT-3-1
Anticodon:LysCTT
tRNA_number:trna32
Chromosome:16
Strand:-
Coordinate:Start Site(bp): 3207445        End Site(bp): 3207478



tsRNA Association Statistics

Total Associated Disease Number:17
More Information
Network:
(Display the first 15 nodes)



Disease Information

 MeSHDisease Ontology
Disease ID:D001943DOID:1612
Disease Name:Breast Neoplasmsbreast cancer
Category:MeSHDisease Ontology
Type:Neoplasms//Skin and Connective Tissue Diseasesdisease of anatomical entity//disease of cellular proliferation
Define:Tumors or cancer of the human BREAST.A thoracic cancer that originates in the mammary gland.
Alias:Breast Cancer//Breast Carcinoma//Breast Tumors//Cancer of Breast//Cancer of the Breast//Human Mammary Carcinoma//Malignant Neoplasm of Breast//Malignant Tumor of Breast//Mammary Cancer//Mammary Carcinoma, Human//Mammary Neoplasm, Human//Mammary Neoplasms, Human//Neoplasms, Breast//Tumors, Breastbreast tumor//malignant neoplasm of breast//malignant tumor of the breast//mammary cancer//mammary neoplasm//mammary tumor//primary breast cancer



Disease Association Statistics

Total Associated tsRNA Number:549
More Information
Network:
(Display the first 15 nodes)



Evidence Support

Strong Evidence:N/A
Weak Evidence:High-throughput sequencing



Reference

[1] PubMed ID:32814252
Disease Name:Breast Neoplasms
Tissue:Plasma
Dysfunction Pattern:Up-Regulation
Validated Method:High-throughput sequencing
Description:Thirty tRFs and tiRNAs were selected by high-throughput sequencing in screening phase and then assessed in training, testing, and external validation phases byqRT-PCR. Six tRFs (tRF-Glu-CTC-003, tRF-Gly-CCC-007, tRF-Gly-CCC-008, tRF-Leu-CAA-003, tRF-Ser-TGA-001, and tRF-Ser-TGA-002) were found significantly downregulated in plasma samples of patients with EBC compared with normal controls.
Comparision:Cancer VS Normal
Mechanism:N/A